Literature DB >> 32445339

Serum Free Light Chain Assay: Shift Toward a Higher κ/λ Ratio.

Barbara Rindlisbacher1,2, Christof Schild1,2, Florence Egger2, Vera U Bacher2,3, Thomas Pabst4, Alexander Leichtle1, Martin Andres3, Nazanin Sédille-Mostafaie1,2.   

Abstract

BACKGROUND: The analysis of serum free light chains (FLCs) is clinically relevant for the diagnosis and therapeutic management of clonal plasma cell disorders. This study compares the performance of monoclonal and polyclonal FLC κ and λ assays in clinical samples determined in a single academic center.
METHODS: Serum FLCs were analyzed from 102 patients using the Freelite (Binding Site) and N Latex (Siemens) assays on the BN ProSpec System (Siemens). When available, data for protein electrophoresis, immunofixation, C-reactive protein, and estimated glomerular filtration rate (eGFR) were combined with FLC results to evaluate performance.
RESULTS: Method evaluation showed acceptable imprecision and inaccuracy measures of <4.4% and 12.9%, respectively. Poor agreement between the methods was observed, including constant and proportional bias and poor correlation (Kendall τ, 0.671-0.901). The N Latex assay was not affected by the renal impairment estimated by eGFR, unlike the FLC κ/λ ratio results by the Freelite assay. With the Freelite assay, 98% of putative controls without monoclonal gammopathy (n = 42) showed a κ/λ ratio that was above the median of the standard diagnostic range or renal diagnostic range. A shift toward higher κ/λ ratios was also observed when retrospective data between 2011 and 2017 were compared.
CONCLUSIONS: Unlike the Freelite assay, κ/λ ratios analyzed with the N Latex assay were not affected by renal failure. Both methods showed acceptable performances using nephelometry, but they were poorly correlated. A shift toward κ/λ ratios might impair the specificity of borderline increased κ/λ results. This should be considered when interpreting FLC κ and λ results.
© 2019 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32445339     DOI: 10.1093/jalm.2019.029330

Source DB:  PubMed          Journal:  J Appl Lab Med        ISSN: 2475-7241


  4 in total

1.  MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients.

Authors:  Patrick W Mellors; Surendra Dasari; Mindy C Kohlhagen; Taxiarchis Kourelis; Ronald S Go; Eli Muchtar; Morie A Gertz; Shaji K Kumar; Francis K Buadi; Maria A V Willrich; John A Lust; Prashant Kapoor; Martha Q Lacy; David Dingli; Yi Hwa; Amie Fonder; Miriam Hobbs; Susan Hayman; Rahma Warsame; Nelson R Leung; Yi Lin; Wilson Gonsalves; Mustaqeem Siddiqui; Robert A Kyle; S Vincent Rajkumar; David L Murray; Angela Dispenzieri
Journal:  Blood Cancer J       Date:  2021-03-04       Impact factor: 11.037

2.  Alteration of the Gut Microbiome in Chronic Kidney Disease Patients and Its Association With Serum Free Immunoglobulin Light Chains.

Authors:  Fengping Liu; Xuefang Xu; Lin Chao; Ke Chen; Amo Shao; Danqin Sun; Yan Hong; Renjing Hu; Peng Jiang; Nan Zhang; Yonghong Xiao; Feng Yan; Ninghan Feng
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

3.  Using Two Detection Methods to Observe the Changes and Significance of Free Light Chain in Serum and Urine in Patients with Renal Insufficiency.

Authors:  Lengnan Xu; Ban Zhao; Ying Sun; Songlan Wang; Xianguang Chen; Yonghui Mao
Journal:  Biomed Res Int       Date:  2022-03-29       Impact factor: 3.411

4.  Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis.

Authors:  Hajer Abroud; Asma Beldi-Ferchiou; Vincent Audard; François Lemonnier; Fabien Le Bras; Karim Belhadj; Anissa Moktefi; Elsa Poullot; Khalil El Karoui; Jehan Dupuis; Alizée Maarek; Louise Roulin; Marie-Hélène Delfau-Larue; Silvia Oghina; Mounira Kharoubi; Mélanie Bézard; Amira Zaroui; Thibaud Damy; Valérie Molinier-Frenkel
Journal:  EJHaem       Date:  2022-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.